ClinicalTrials.gg
Active, not recruitingNCT05288166CYCLONE 3Updated Jul 1, 2026Results posted

A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

A Phase 3 interventional study of Abemaciclib and Abiraterone in Prostatic Neoplasms, Neoplasm Metastasis and Urogenital Neoplasms, sponsored by Eli Lilly and Company. Active, not recruiting at 266 sites in 24 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-01.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
925
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies testing abemaciclib in Prostatic Neoplasms — 1 open to participants now, 3 under way, 2 of them phase 3. abemaciclib · Prostatic Neoplasms.

Enrollment
Largest of 10
925 · median 15
Started
2022
with 1 other
Phase 3
Only one
of the 10
Registered
7th of 10
by date
Lead sponsor
4 of 10
Eli Lilly and Company

Among the 10 studies testing abemaciclib in Prostatic Neoplasms, this one has the largest enrollment, is one of 2 that started in 2022, is the only one in phase 3, and was the 7th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,579 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

1 of the 10 studies testing abemaciclib in Prostatic Neoplasms is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About abemaciclib

abemaciclib: first FDA approval 2017 (VERZENIO), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,228 Prostatic Neoplasms studies recruiting now, 927 (75%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing abemaciclib in Prostatic Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to learn whether adding abemaciclib to abiraterone plus prednisone prolongs the time before prostate cancer gets worse. Participation may last approximately 60 months.

03

Conditions studied

  • Prostatic Neoplasms
  • Neoplasm Metastasis
  • Urogenital Neoplasms
  • Physiological Effects of Drugs
  • Antineoplastic Agents
  • Antineoplastic Agents, Hormonal
  • Androgens
  • Hormones
  • Hormones, Hormone Substitutes, and Hormone Antagonists
  • Abiraterone Acetate
  • Steroid Synthesis Inhibitors
  • Cytochrome P-450
  • Enzyme Inhibitors
  • Prednisone
  • Prednisolone
  • Cyclin-Dependent Kinase 4
  • Cyclin-Dependent Kinase 6

Keywords

  • Metastatic Hormone Sensitive Prostate Cancer
  • mHSPC
  • Stage IV Prostate Cancer
  • Recurrent Prostate Cancer
  • De Novo Metastatic Prostate Cancer
  • High-Risk
  • Visceral metastasis
  • Cyclin-Dependent Kinase 4 (CDK4)
  • Cyclin-Dependent Kinase 6 (CDK6)
  • CDK4
  • CDK6
  • CDK4/6
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adenocarcinoma of the prostate (as the predominant histology)
  • High-risk hormone-sensitive prostate cancer. High risk is defined as:

    • Greater than or equal to (≥)4 bone metastases by bone scan and/or
    • ≥1 visceral metastases by computed tomography or magnetic resonance imaging
  • Must have initiated androgen deprivation therapy (ADT) with luteinizing hormone-releasing hormone (LHRH) agonist/antagonist or bilateral orchiectomy prior to randomization. Up to 3 months of ADT prior to randomization is permitted with or without first-generation anti-androgen.
  • Adequate organ function
  • (ECOG) performance status of 0 or 1

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with abemaciclib or any other cyclin dependent kinase 4 and 6 (CDK4 \& 6) inhibitor
  • Development of prostate cancer in the context of castrate levels of testosterone
  • Received any prior systemic therapy for metastatic prostate cancer (including agents), except for ADT and first-generation anti-androgen
  • cardiovascular disease as evidenced by myocardial infarction, arterial thrombotic events, or severe/unstable angina in the past 6 months, or Class II to IV heart failure
  • History of syncope of cardiovascular etiology, ventricular arrhythmia of pathological origin, or sudden cardiac arrest. Chronic and hemodynamically stable atrial arrhythmia well-controlled on medical therapy is permitted
  • Uncontrolled hypertension
  • Clinically active or chronic liver disease, moderate/severe hepatic impairment
  • Known untreated central nervous system (CNS) metastasis. Participants with a history of treated are eligible if stable for at least 8 weeks prior to randomization and off for at least 2 weeks prior to randomization
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
925 participants (actual)

Study arms

  • Experimental
    Abemaciclib

    Participants received 200 milligram (mg) abemaciclib twice daily (BID) in combination with standard doses of 1000 mg abiraterone acetate once daily and 5mg prednisone BID administered orally on a continuous dosing schedule on days 1 through 28 of a 28-day cycle until radiographic and/or symptomatic progression or until another discontinuation criterion is met.

    Drug: Abemaciclib · Drug: Abiraterone · Drug: Prednisone or Prednisolone

  • Active comparator
    Placebo

    Participants received placebo BID in combination with standard doses of 1000 mg abiraterone acetate once daily and 5mg prednisone BID administered orally on a continuous dosing schedule on days 1 through 28 of a 28-day cycle until radiographic and/or symptomatic progression or until another discontinuation criterion is met.

    Drug: Abiraterone · Drug: Prednisone or Prednisolone · Drug: Placebo for Abemaciclib

Interventions

  • Administered orally.

    Also known as: LY2835219

  • Administered orally.

  • DrugPrednisone or Prednisolone

    Drug pages: Prednisone · Prednisolone

    Administered orally.

  • DrugPlacebo for Abemaciclib

    Administered orally.

06

What researchers measure

Primary outcomes

  1. Radiographic Progression-Free Survival (rPFS) Assessed by Investigator

    The rPFS time is measured from the date of randomization to the earliest date of investigator determined radiographic disease progression (by objective radiographic disease assessment per response evaluation criteria in solid tumors (RECIST) version 1.1 for soft tissue AND/OR radionuclide bone scan using prostate cancer working group 3 -PCWG3 criteria for bone) or death from any cause, whichever occurs first.

    Time frame: From Date of Randomization to Radiographic Disease Progression or Death from Any Cause (up to 22 months)

Secondary outcomes

  1. Radiographic Progression-Free Survival (rPFS) Assessed by Blinded Independent Central Review (BICR)

    The rPFS time is measured from the date of randomization to the earliest date of investigator determined radiographic disease progression (by objective radiographic disease assessment per response evaluation criteria in solid tumors (RECIST) version 1.1 for soft tissue AND/OR radionuclide bone scan using prostate cancer working group 3 -PCWG3 criteria for bone) or death from any cause, whichever occurs first.

    Time frame: From Date of Randomization to Radiographic Disease Progression or Death from Any Cause (up to 22 months)

  2. Castration-resistant Prostate Cancer (CRPC)-Free Survival

    CRPC-free survival is defined as the time from the date of randomization to the earliest date of castration resistance, as demonstrated by any of the following (whichever occurs earliest): Confirmed prostate-specific antigen (PSA) progression with serum testosterone ≤50 nanogram/deciliter (ng/dL) (≤1.73 nanomoles per liter(nmol/L)). Investigator-assessed radiographic progression with serum testosterone ≤50 ng/dL (≤1.73 nmol/L). Death from any cause.

    Time frame: Randomization to the earliest date of PSA or radiographic progression with a testosterone level of ≤50 ng/dL; or death from any cause (up to 22 months)

  3. Overall Survival (OS)

    The OS time is measured from the date of randomization to the date of death from any cause. If the participant was alive or lost to follow-up at the time of data analysis, OS data were censored on the last date the participant was known to be alive.

    Time frame: From Date of Randomization to Date of Death Due to Any Cause (Up to 22 Months)

  4. Time to Pain Progression

    Time frame: Randomization to pain progression (up to 22 months)

  5. Time to Deterioration in Health-Related Quality of Life (HRQoL) Measured by Functional Assessment of Cancer Therapy-Prostate (FACT-P) - Physical Well-Being Subscale

    Time to deterioration in health-related quality of life (HRQoL) was defined as the time from randomization to the date of the first clinically meaningful HRQoL deterioration on 2 consecutive measurements. HRQoL evaluation was performed using the FACT-P questionnaire. Physical Well-Being subscale is a subsection of FACT-P questionnaire. FACT-P consists of 39 core items to assess health related quality of life in participants with prostate cancer. It consisted of 5 sub-scales assessing physical well-being (7 items), social/family well-being (7 items), emotional well-being (6 items), functional well-being (7 items), and prostate cancer subscale (12 items). Each item is rated from 0 (Not at all) to 4 (Very much) and combined to produce subscale scores. FACT-P total score was the sum of all 5 subscale scores. It ranged from 0 to 156 with higher score indicating better quality of life. Physical well-being subscale score ranges from 0 to 28 with high score indicating better quality of life.

    Time frame: Randomization to the date of the first clinically meaningful HRQoL deterioration (up to 22 months)

  6. Time to Deterioration in Health-Related Quality of Life (HRQoL) Measured by Functional Assessment of Cancer Therapy-Prostate (FACT-P) - Prostate Cancer Subscale

    Time to deterioration in health-related quality of life (HRQoL) was defined as the time from randomization to the date of the first clinically meaningful HRQoL deterioration on 2 consecutive measurements. HRQoL evaluation was performed using the FACT-P questionnaire. Prostate Cancer Subscale is a subsection of FACT-P questionnaire. FACT-P consists of 39 core items to assess health related quality of life in participants with prostate cancer. It consisted of 5 sub-scales assessing physical well-being (7 items), social/family well-being (7 items), emotional well-being (6 items), functional well-being (7 items), and prostate cancer subscale (12 items). Each item is rated from 0 (Not at all) to 4 (Very much) and combined to produce subscale scores. FACT-P total score was the sum of all 5 subscale scores. It ranged from 0 to 156 with higher score indicating better quality of life. Prostate cancer subscale score ranges from 0 to 48 with high score indicating better quality of life.

    Time frame: Randomization to the date of the first clinically meaningful HRQoL deterioration (up to 22 months)

  7. Pharmacokinetics (PK): Maximum Plasma Concentration at Steady State (Cmax,ss) of Abemaciclib

    Maximum plasma concentration at steady state (Cmax,ss) of abemaciclib was evaluated.

    Time frame: Predose on Cycle 1 Day 1, Predose and Predose on Cycle 2 Day 1 and Predose on Cycle 3 Day 1 (28 Day Cycles)

07

Results

Posted Jun 27, 2025

Participant flow

Participant flow — Overall Study
MilestoneAbemaciclibPlacebo
Started463462
Received at least one dose of study drug460460
Completed4739
Not completed416423
Withdrew: Adverse event10
Withdrew: Lost to follow-up20
Withdrew: Physician decision02
Withdrew: Screen failure11
Withdrew: Withdrawal by subject42
Withdrew: On study treatment408418

Outcome measures

PrimaryRadiographic Progression-Free Survival (rPFS) Assessed by Investigator

The rPFS time is measured from the date of randomization to the earliest date of investigator determined radiographic disease progression (by objective radiographic disease assessment per response evaluation criteria in solid tumors (RECIST) version 1.1 for soft tissue AND/OR radionuclide bone scan using prostate cancer working group 3 -PCWG3 criteria for bone) or death from any cause, whichever occurs first.

Time frame:
From Date of Randomization to Radiographic Disease Progression or Death from Any Cause (up to 22 months)
Reported as:
Median · Months
Radiographic Progression-Free Survival (rPFS) Assessed by Investigator
MonthsAbemaciclibPlacebo
Radiographic Progression-Free Survival (rPFS) Assessed by InvestigatorNA (NA to NA)NA (NA to NA)
SecondaryRadiographic Progression-Free Survival (rPFS) Assessed by Blinded Independent Central Review (BICR)

The rPFS time is measured from the date of randomization to the earliest date of investigator determined radiographic disease progression (by objective radiographic disease assessment per response evaluation criteria in solid tumors (RECIST) version 1.1 for soft tissue AND/OR radionuclide bone scan using prostate cancer working group 3 -PCWG3 criteria for bone) or death from any cause, whichever occurs first.

Time frame:
From Date of Randomization to Radiographic Disease Progression or Death from Any Cause (up to 22 months)
Reported as:
Median · Months
Radiographic Progression-Free Survival (rPFS) Assessed by Blinded Independent Central Review (BICR)
MonthsAbemaciclibPlacebo
Radiographic Progression-Free Survival (rPFS) Assessed by Blinded Independent Central Review (BICR)NA (11.11 to NA)NA (13.02 to NA)
SecondaryCastration-resistant Prostate Cancer (CRPC)-Free Survival

CRPC-free survival is defined as the time from the date of randomization to the earliest date of castration resistance, as demonstrated by any of the following (whichever occurs earliest): Confirmed prostate-specific antigen (PSA) progression with serum testosterone ≤50 nanogram/deciliter (ng/dL) (≤1.73 nanomoles per liter(nmol/L)). Investigator-assessed radiographic progression with serum testosterone ≤50 ng/dL (≤1.73 nmol/L). Death from any cause.

Time frame:
Randomization to the earliest date of PSA or radiographic progression with a testosterone level of ≤50 ng/dL; or death from any cause (up to 22 months)
Reported as:
Median · Months
Castration-resistant Prostate Cancer (CRPC)-Free Survival
MonthsAbemaciclibPlacebo
Castration-resistant Prostate Cancer (CRPC)-Free SurvivalNA (14.86 to NA)NA (NA to NA)
SecondaryOverall Survival (OS)

The OS time is measured from the date of randomization to the date of death from any cause. If the participant was alive or lost to follow-up at the time of data analysis, OS data were censored on the last date the participant was known to be alive.

Time frame:
From Date of Randomization to Date of Death Due to Any Cause (Up to 22 Months)
Reported as:
Median · Months
Overall Survival (OS)
MonthsAbemaciclibPlacebo
Overall Survival (OS)NA (NA to NA)NA (NA to NA)
SecondaryTime to Pain Progression
Time frame:
Randomization to pain progression (up to 22 months)
Reported as:
Median · Months
Time to Pain Progression
MonthsAbemaciclibPlacebo
Time to Pain ProgressionNA (NA to NA)19.13 (15.35 to NA)
SecondaryTime to Deterioration in Health-Related Quality of Life (HRQoL) Measured by Functional Assessment of Cancer Therapy-Prostate (FACT-P) - Physical Well-Being Subscale

Time to deterioration in health-related quality of life (HRQoL) was defined as the time from randomization to the date of the first clinically meaningful HRQoL deterioration on 2 consecutive measurements. HRQoL evaluation was performed using the FACT-P questionnaire. Physical Well-Being subscale is a subsection of FACT-P questionnaire. FACT-P consists of 39 core items to assess health related quality of life in participants with prostate cancer. It consisted of 5 sub-scales assessing physical well-being (7 items), social/family well-being (7 items), emotional well-being (6 items), functional well-being (7 items), and prostate cancer subscale (12 items). Each item is rated from 0 (Not at all) to 4 (Very much) and combined to produce subscale scores. FACT-P total score was the sum of all 5 subscale scores. It ranged from 0 to 156 with higher score indicating better quality of life. Physical well-being subscale score ranges from 0 to 28 with high score indicating better quality of life.

Time frame:
Randomization to the date of the first clinically meaningful HRQoL deterioration (up to 22 months)
Reported as:
Median · Months
Time to Deterioration in Health-Related Quality of Life (HRQoL) Measured by Functional Assessment of Cancer Therapy-Prostate (FACT-P) - Physical Well-Being Subscale
MonthsAbemaciclibPlacebo
Time to Deterioration in Health-Related Quality of Life (HRQoL) Measured by Functional Assessment of Cancer Therapy-Prostate (FACT-P) - Physical Well-Being SubscaleNA (NA to NA)NA (NA to NA)
SecondaryTime to Deterioration in Health-Related Quality of Life (HRQoL) Measured by Functional Assessment of Cancer Therapy-Prostate (FACT-P) - Prostate Cancer Subscale

Time to deterioration in health-related quality of life (HRQoL) was defined as the time from randomization to the date of the first clinically meaningful HRQoL deterioration on 2 consecutive measurements. HRQoL evaluation was performed using the FACT-P questionnaire. Prostate Cancer Subscale is a subsection of FACT-P questionnaire. FACT-P consists of 39 core items to assess health related quality of life in participants with prostate cancer. It consisted of 5 sub-scales assessing physical well-being (7 items), social/family well-being (7 items), emotional well-being (6 items), functional well-being (7 items), and prostate cancer subscale (12 items). Each item is rated from 0 (Not at all) to 4 (Very much) and combined to produce subscale scores. FACT-P total score was the sum of all 5 subscale scores. It ranged from 0 to 156 with higher score indicating better quality of life. Prostate cancer subscale score ranges from 0 to 48 with high score indicating better quality of life.

Time frame:
Randomization to the date of the first clinically meaningful HRQoL deterioration (up to 22 months)
Reported as:
Median · Months
Time to Deterioration in Health-Related Quality of Life (HRQoL) Measured by Functional Assessment of Cancer Therapy-Prostate (FACT-P) - Prostate Cancer Subscale
MonthsAbemaciclibPlacebo
Time to Deterioration in Health-Related Quality of Life (HRQoL) Measured by Functional Assessment of Cancer Therapy-Prostate (FACT-P) - Prostate Cancer SubscaleNA (NA to NA)NA (NA to NA)
SecondaryPharmacokinetics (PK): Maximum Plasma Concentration at Steady State (Cmax,ss) of Abemaciclib

Maximum plasma concentration at steady state (Cmax,ss) of abemaciclib was evaluated.

Time frame:
Predose on Cycle 1 Day 1, Predose and Predose on Cycle 2 Day 1 and Predose on Cycle 3 Day 1 (28 Day Cycles)
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
Pharmacokinetics (PK): Maximum Plasma Concentration at Steady State (Cmax,ss) of Abemaciclib
nanogram per milliliter (ng/mL)Abemaciclib
Pharmacokinetics (PK): Maximum Plasma Concentration at Steady State (Cmax,ss) of Abemaciclib308.3 ± 50

Adverse events

Collected over Baseline up to 22 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Abemaciclib47/460 (10.2%)145/460 (31.5%)445/460 (96.7%)
Placebo32/460 (7%)68/460 (14.8%)380/460 (82.6%)
Most frequent serious events
Showing 10 of 162
Most frequent serious events
EventAbemaciclibPlacebo
PneumoniaInfections and infestations19/4604/460
Urinary tract infectionInfections and infestations11/4603/460
AnaemiaBlood and lymphatic system disorders9/4600/460
HypokalaemiaMetabolism and nutrition disorders9/4603/460
Acute kidney injuryRenal and urinary disorders8/4600/460
FatigueGeneral disorders7/4601/460
Cardiac failureCardiac disorders5/4602/460
Covid-19Infections and infestations5/4603/460
Atrial fibrillationCardiac disorders4/4602/460
Myocardial infarctionCardiac disorders4/4604/460
Most frequent other events
Showing 10 of 40
Most frequent other events
EventAbemaciclibPlacebo
DiarrhoeaGastrointestinal disorders301/46062/460
AnaemiaBlood and lymphatic system disorders252/46058/460
NeutropeniaBlood and lymphatic system disorders217/46013/460
FatigueGeneral disorders178/46091/460
HypokalaemiaMetabolism and nutrition disorders133/46063/460
Blood creatinine increasedInvestigations130/46017/460
LeukopeniaBlood and lymphatic system disorders126/46010/460
ThrombocytopeniaBlood and lymphatic system disorders125/46014/460
NauseaGastrointestinal disorders116/46041/460
Hot flushVascular disorders69/46098/460

Baseline characteristics

All randomized participants.

Age, Continuous
Age, Continuous(years)AbemaciclibPlaceboTotal
Mean68.80 ± 8.1669.30 ± 8.0769.00 ± 8.11
Sex: Female, Male
Sex: Female, Male(Participants)AbemaciclibPlaceboTotal
Female000
Male463462925
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)AbemaciclibPlaceboTotal
Hispanic or Latino115126241
Not Hispanic or Latino276271547
Unknown or Not Reported7265137
Race (NIH/OMB)
Race (NIH/OMB)(Participants)AbemaciclibPlaceboTotal
American Indian or Alaska Native272754
Asian122120242
Native Hawaiian or Other Pacific Islander101
Black or African American171532
White278286564
More than one race9514
Unknown or Not Reported9918
Region of Enrollment
Region of Enrollment(Participants)AbemaciclibPlaceboTotal
Argentina403979
Australia282957
Belgium303
Brazil465399
Canada112
China6570135
Czechia151126
France14923
Germany242246
Greece246
Hungary5510
Israel7916
Italy121224
Japan393069
Mexico343468
Netherlands257
Poland121426
Romania325
South Korea7411
Spain161430
Taiwan8715
Turkey212041
United Kingdom718
United States5267119
08

Study locations

266 sites

Showing the first 100 of 266 sites across 24 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2022 to primary completion in Feb 2024, 22 months.

Results were first posted in Jun 2025, 1 year 4 months after primary completion.

Of 126 industry-sponsored phase 3 interventional studies under Prostatic Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 53. This study's 22 months is below that.

Counting every sponsor, half of 265 studies reached it within 57 months; a quarter within 31 and three quarters within 100.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 10, 2022
First posted
Mar 21, 2022
StartActual
Apr 14, 2022
Primary completionActual
Feb 15, 2024
CompletionEst.
Oct 2027
Results first posted
Jun 27, 2025
Last update
Jul 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05288166
Responsible party
Sponsor
First posted
Mar 21, 2022
Start date
Apr 14, 2022
Primary completion
Feb 15, 2024
Completion
Oct 2027 (estimated)
Results posted
Jun 27, 2025
Last update
Jul 1, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abemaciclib

Start the discussion